Skip to content
value.today

Vavotar Life Sciences, LLC

🇺🇸 Cumming, Georgia, USAHealth CareFounded 2015
Total raised
$156 M
5 rounds on record
Latest round
$10 M
Nov 2018
First round on record
Mar 2016
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vavotar Life Sciences, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2018$10 MNo. 5$10 to $50 million

Vavotar Life Sciences, LLC: Raise no. 5, Nov 2018

Investors in this round

31 investors had bought by the notice of Jan 18, 2019: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
$6,250
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$156,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Charles Farrahar · Executive Officer
  • Steve Gorlin · Executive Officer, Director
  • Andrew Danielsen · Director
  • James A. Rogers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Finsoft Consultants, Inc. · New York, New YorkSold in CO, CT, FL, GA, NY, OK, PA, TN, TX
  • Ashley Johnson · Destin, FloridaSold in CO, CT, FL, GA, NY, OK, PA, TN, TX
  • Virginia Dadey · Palm Beach, FloridaSold in CO, CT, FL, GA, NY, OK, PA, TN, TX

Signed by Charles Farrahar, Cfo. Source: SEC Form D, newest notice filed Jan 18, 2019. Read the notice at the SEC.

equitySEC
Aug 2016$81 MNo. 4$50 to $250 million

Vavotar Life Sciences, LLC: Raise no. 4, Aug 2016

Investors in this round

1 investor had bought by the notice of Sep 23, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$81 M of $81 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Charles Farrahar · Executive Officer
  • Jesse W. Crowne · Executive Officer
  • Martin A. Bell · Executive Officer
  • Steve Gorlin · Executive Officer, Director
  • Patrick W. Soon-Shiong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles Farrahar, Cfo. Source: SEC Form D, newest notice filed Sep 23, 2016. Read the notice at the SEC.

equitySEC
Aug 2016$21 MNo. 3$10 to $50 million

Vavotar Life Sciences, LLC: Raise no. 3, Aug 2016

Investors in this round

3 investors had bought by the notice of Sep 22, 2016: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Charles Farrahar · Executive Officer
  • Jesse W. Crowne · Executive Officer
  • Martin A. Bell · Executive Officer
  • Steve Gorlin · Executive Officer, Director
  • Patrick W. Soon-Shiong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles Farrahar, Cfo. Source: SEC Form D, newest notice filed Sep 22, 2016. Read the notice at the SEC.

equitySEC
Aug 2016$41 MNo. 2$10 to $50 million

Vavotar Life Sciences, LLC: Raise no. 2, Aug 2016

Investors in this round

1 investor had bought by the notice of Sep 21, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$41 M of $41 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Charles Farrahar · Executive Officer
  • Jesse W. Crowne · Executive Officer
  • Martin A. Bell · Executive Officer
  • Steve Gorlin · Executive Officer, Director
  • Patrick W. Soon-Shiong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles Farrahar, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 21, 2016. Read the notice at the SEC.

equitySEC
Mar 2016$4 MNo. 1$2 to $10 million

Vavotar Life Sciences, LLC: Raise no. 1, Mar 2016

Investors in this round

11 investors had bought by the notice of May 16, 2016: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Charles Farrahar · Executive Officer
  • Jesse W. Crowne · Executive Officer
  • Martin A. Bell · Executive Officer
  • Steve Gorlin · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles Farrahar, Cfo. Source: SEC Form D, newest notice filed May 16, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vavotar Life Sciences, LLC had no revenue when it filed its newest notice of a funding round (Jan 2019).

    SEC Form D (revenue range) · Jan 2019

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jan 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Vavotar Life Sciences, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 31 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vavotar Life Sciences, LLC
NameRoleNamed in
Charles FarraharExecutive officerJan 2019
Steve GorlinExecutive officerJan 2019
Jesse W. CrowneExecutive officerSep 2016
Martin A. BellExecutive officerSep 2016
Andrew DanielsenDirectorJan 2019
James A. RogersDirectorJan 2019
Steve GorlinDirectorJan 2019
Patrick W. Soon-ShiongDirectorSep 2016